Clinical Trials
16 trialsNCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT06097728 2026-04-28
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT05732831 2026-04-21
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07510815 2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT04665206 2026-04-02
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Phase 1/2 Recruiting
NCT05873686 2026-03-03
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT05245500 2025-12-05
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
Phase 1 Recruiting
NCT06452160 2024-08-09
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
Phase 1 Recruiting
NCT05627960 2022-11-28
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical Inc.
Phase 1 Recruiting